Gabriel Ganley, a 22-year-old [1] bodybuilder and social-media influencer, died of hypertrophic cardiomyopathy according to an autopsy report released Monday [1].
The death of a young athlete highlights the risks associated with undiagnosed heart conditions and the potential dangers of performance-enhancing substances in fitness culture.
The Instituto Médico Legal (IML) in Brazil issued the report on May 25, 2026 [1]. The document identifies the cause of death as hypertrophic cardiomyopathy, a condition characterized by the thickening of the heart muscle [2]. This disease can lead to sudden cardiac arrest, particularly in athletes who engage in high-intensity physical activity [3].
Medical specialists said the condition may be linked to the indiscriminate use of anabolic steroids [3]. While hypertrophic cardiomyopathy can be hereditary, the use of certain substances can exacerbate heart wall thickening and increase the risk of sudden death [3].
Ganley was a prominent figure in the bodybuilding community, where he used social media to share his fitness journey. The IML report provides a definitive medical explanation for the sudden nature of his death [2].
Authorities and health experts in Brazil have used the case to discuss the importance of cardiac screening for athletes. Because hypertrophic cardiomyopathy often presents no symptoms until a fatal event occurs, regular check-ups are recommended for those in high-strain sports [3].
“Gabriel Ganley died of hypertrophic cardiomyopathy according to an autopsy report.”
This case underscores a critical intersection between genetic predispositions and the use of performance-enhancing drugs in professional bodybuilding. Hypertrophic cardiomyopathy is a leading cause of sudden cardiac death in young athletes, and the potential compounding effect of anabolic steroids may increase the lethality of the condition, prompting calls for stricter medical oversight in the fitness industry.
